Viking Therapeutics, Inc.

NASDAQ:VKTX

Biotechnology

Healthcare
$26.17 +1.06%

+$0.32 today

Market cap
$3.34B
Beta
0.68
P/E (TTM)
-7.5
EPS (TTM)
-$4.09
52W Low $22.96High $43.15

Volume 2.87M

Average 2.20M

VKTX Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Viking Therapeutics, Inc.NASDAQ: VKTX

Revenue · Q2 FY2026 · quarter ended Jun 2026

Revenue remains negative

Q2 FY2026 revenue was $0, compared with $0 a year earlier. Trailing-twelve-month revenue was $0.

Context

  • Revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMJun 2026
$0— YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How VKTX compares with its peers on the latest reported figures

  • VKTX's LTM Jun 2026 revenue of $0 is the 5th highest of the 7 companies compared; the peer median is $21.98M.
VKTX Competitors Peer median
Revenue for VKTX and competitors
Company Period LTM YoY 3-year CAGR
MDGLMadrigal Pharmaceuticals, Inc.LTM Jun 2026$1.28B +149.0%—
SEPNSepterna, Inc.LTM Sep 2026$96.27M +336.7%—
VTVTvTv Therapeutics Inc.LTM Mar 2026$36.84M +216600.0%—
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 2026$7.12M -88.9%-39.7%
VKTXViking Therapeutics, Inc.LTM Jun 2026$0 ——
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$0 ——
KLRAKailera Therapeutics, Inc.FY2025$0 ——
Peer median (excluding VKTX) $21.98M+242.9%-39.7%

Competitors are the stored peer set for VKTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0000431K
Gross Profit0000(431K)
Gross Margin—————
Research & Development44.98M54.23M63.81M101.64M344.96M
Selling, General & Admin10.7M16.12M37.02M49.28M48.39M
Operating Expenses55.68M70.36M100.83M150.92M393.34M
Depreciation & Amortization296K291K292K346K431K
EBITDA(54.68M)(68.52M)(85.52M)(109.52M)(359.15M)
EBITDA Margin—————
Operating Income(55.68M)(70.36M)(100.83M)(150.92M)(393.34M)
Operating Margin—————
Interest Income703K1.59M15.02M40.94M33.7M
Interest Expense18K59K88K94K0
Other Income / Expenses692K1.49M14.93M40.96M33.7M
Income Before Tax(54.99M)(68.87M)(85.9M)(109.96M)(359.64M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(54.99M)(68.87M)(85.9M)(109.96M)(359.64M)
Net Margin—————
EPS (Basic)(0.70)(0.88)(0.91)(1.01)(3.19)
EPS (Diluted)(0.70)(0.88)(0.91)(1.01)(3.19)
Weighted Avg Shares77.2M76.83M94.35M109.04M112.67M
Weighted Avg Shares (Diluted)77.2M76.83M94.35M109.04M112.67M

Viking Therapeutics, Inc.

NASDAQ:VKTX

Intrinsic Alpha fair value

Locked

Current Price

$26.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.